Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 194 for “"hydroxyurea"”.
-
Tissue specific accumulation of hydroxyurea in elasmobranchs
Hydroxyurea is an antibiotic and antiproliferative agent used clinically in the treatment of select cancers, sickle cell anemia, HIV, and myeloproliferative diseases. Hydroxyurea has never been detected in elasmobranch tissues and has only been detected in trace amounts in a single eukaryote. Using …
-
Defining a novel role of hydroxyurea on erythrocytes
Thesis (Ph. D.)--Michigan State University. Chemistry, 2008
-
Stroke Training, Research, and Education Toward Capacity With Hydroxyurea (Stretch)
… identifies children at risk, and treatment with hydroxyurea. This study will inform how public health leaders can mitigate stroke risk among children with SCA in sub-Saharan Africa and how TCD screening fits into a larger context of providing safe, effective care. Methods: Stroke Training, …
-
Pathways of Hydroxyurea Synthesis in the Mitochondria of the Little Skate (Leucoraja erincea)
Hydroxyurea (HU) is an anti-proliferative and anti-microbial compound that is widely used in medical therapy but is also found to occur naturally in different phylogenetic groups. However, it is still unknown how this compound is endogenously synthesized. I hypothesized that HU is synthesized …
-
Barriers to hydroxyurea use in sickle cell disease: perspectives of providers, families, and adults
… on morbidity, mortality, and quality of life. Hydroxyurea has been FDA approved since 1998 as a disease-modifying therapy for SCD. However, hydroxyurea has not been optimally utilized for those with SCD. The purpose of this study was to evaluate reasons for hydroxyurea use, from the …
-
THE GENETIC REGULATION OF THE RESPONSE OF HEMATOPOIETIC STEM/PROGENITOR CELLS TO THE CYTOSTATIC AGENT HYDROXYUREA
… were less susceptible to the cytostatic agent hydroxyurea (HU) than the short-lived D2 mouse strain. A quantitative trait locus (QTL) analysis revealed a region of proximal chromosome 7 that regulates this response to HU. Congenic mouse strains were generated and phenotypic analysis confirmed …
-
A Meta-Analysis of Hydroxyurea Use for β-thalassemia: Implications for Clinical Practice and Medical Education
… of the problems associated with current therapy. Hydroxyurea (HU), an oral chemotherapeutic drug, is expected to increase hemoglobin, thereby minimizing the burden of blood transfusion and its complications. The objective of this study was to conduct a systematic review and meta-analysis to …
-
Examining the Effect of Hydroxyurea Treatment on Acute Care Spending and Utilization among Patients with Sickle Cell Disease
… often with particularly high emergency care use. Hydroxyurea (HU), an inexpensive therapeutic drug, has proven to be effective at reducing pain crises. However, HU is underutilized for a variety of reasons including lack of insurance coverage, misperceptions and negative beliefs, and lack of …
-
Predictors Of Use Of Hydroxyurea And Its Impact On Clinical And Economic Outcomes Among Children With Sickle Cell Disease
… assess the prevalence and predictors of use of hydroxyurea (HU) and its impact on clinical and economic outcomes in pediatric patients with sickle cell disease (SCD) enrolled in Medicaid. Methods: A cohort of patients with SCD was identified in 2006 using ICD-9-CM codes from Medicaid claims from …
-
The effect of hydroxyurea treatment on DNA methylation and gene expression in essential thrombocythaemia and polycythaemia vera: a cross-species study
… platelets leading to thrombosis and haemorrhage. Hydroxyurea (HU), is the first line treatment for high-risk PV and ET patients since it effectively reduces the haematocrit, platelets and white blood cells counts. Mechanistically, HU acts by inhibiting the ribonucleotide reductase enzyme, blocking …
-
Review of economic studies of sickle cell disease and adherence to hydroxyurea and clinical and economic outcomes among Texas Medicaid enrollees with sickle cell disease
… economic burden of SCD in the U.S.; 2) assessed hydroxyurea medication adherence and its association with vaso-occlusive crisis (VOC)-related events and healthcare utilization and costs. The systematic review (N=21 articles) revealed mean total SCD healthcare costs (2019 USD) ranged from $19,464 …
-
Αξιολόγηση της αποτελεσματικότητας και της ασφάλειας της χορήγησης υδροξυουρίας στη λειτουργία των οργάνων παιδιών και νεαρών ενηλίκων με δρεπανοκυτταρική νόσο
… which is characterized by phenotypic diversity. Hydroxyurea is a myelosuppresive cytostatic drug that has been used, during recent years, in the treatment of children with severe SCD. However, the role of hydroxyurea on early organ damage, when administered early in life, is not clear. The aim of …
-
Use of medications and services for the management of sickle cell disease
… excessive costs. Preventative therapies, such as hydroxyurea, are known to prevent or reduce the frequency of SCD complications. The purpose of this study was to determine medication and healthcare services utilization for the management of SCD, in terms of index and subsequent therapies and …
-
Analysis of essential thrombocythemia and its treatment
… to lower the risk of a thrombotic event. Hydroxyurea and low-dose aspirin have been the gold-standard of treatment for ET patients. This thesis sought to compare the current available therapy with second-line treatments and investigational treatments. Anagrelide is a key second-line …
Page 1 of 10